IL6 and COVID-19: The hypothesis of a central role of STING activation in COVID-19 has been reinforced by: 1-the observation that STING is mostly expressed by endothelial cells and pneumocytes type II [15], i.e. exactly the two main targets of SARS-CoV2; 2-recent reports claiming that drugs blocking IL-6 [16] and STAT-1 [17] downstream of the STING pathway, gave promising results in open trials performed in intensive care units (ICUs); 3-the recent finding that type I IFNs, and to a lesser extent type II IFNs, upregulate ACE2 in human airway epithelial cells, including type II pneumocytes [18].